

ESMO ASIA 2018 INDUSTRY SATELLITE SYMPOSIUM

Making strides in the management of HR+ HER2- metastatic breast cancer

Sponsored by Pfizer Oncology

12:45 – 14:15 | Friday, 23 November 2018

Hall 407, Level 4, Suntec Convention & Exhibition Centre, Singapore

Join a panel of international and regional thought-leaders as they discuss key advances in the field of HR+ HER2- metastatic breast cancer (mBC), with a focus on CDK4/6 inhibitors, as well as how to effectively navigate the mBC patient journey.

CHAIRPERSON



A/Prof Soo Chin Lee
National University
Cancer Institute, Singapore

PRESENTERS



Prof Giuseppe Curigliano
European Institute of Oncology,
Milan, Italy



Dr Amit Agarwal
BLK Super Specialty Hospital,
New Delhi, India



Dr Dwan-Ying Chang
National Taiwan University
Hospital, Taipei, Taiwan

PROGRAM

Time	Topic	Speaker
12:45	Welcome and introduction	A/Prof Soo Chin Lee (Singapore)
12:50	Is there a right fit? Patient profiles in the context of current therapies for HR+ HER2- mBC	Dr Amit Agarwal (India)
13:05	The benefits of CDK4/6 inhibitors for patients with HR+ HER2- mBC	Prof Giuseppe Curigliano (Italy)
13:35	Real-world experience with palbociclib	Dr Dwan-Ying Chang (Taiwan)
13:55	Rapid response panel discussion	All
14:10	Concluding remarks and session close	A/Prof Soo Chin Lee (Singapore)

Complimentary lunch will be provided to symposium attendees.



Pfizer PFE Pte Ltd 80 Pasir Panjang Road #16-81/82, Mapletree Business City, Singapore 117372
Tel: (65) 6403 8888 | Fax: (65) 6403 8868 | www.pfizer.com.sg